Skip to main content

Table 1 Main baseline characteristics of 86 HIV/AgHBs co-infected patients

From: Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

Variables n
Male gender (%) 83 (96. 5%)
Mean age (years) 42 (± 7. 2)
Mode of HIV transmission  
-Men who have unprotected sex with men (%) 64 (74. 4%)
- Exchange of needles among intravenous drug users (%) 16 (18. 6%)
Clinical Variables  
- Advanced hepatic disease 17 (19. 7%)
-Non adherence to treatment 09 (10. 4%)
Treatment Given-HAART  
-Previous use of antiretroviral therapy 81 (94. 1%)
-Patients under LAM + TDF combination therapy 48 (56. 0%)
-Patients under LAM monotherapy 31 (36. 0%)
-Previous use of either LAM or TDF 81 (94. 1%)
- Previous use of LAM 79 (91. 8%)
- Previous use of TDF 48 (55. 8%)
-Time of use of TDF (months) 4-21
-Time of use of LAM (months) 7-144
-Laboratory Variables  
HBeAg positive 42 (48. 9%)
HBV-DNA < 60 UI/mL 50 (58. 1%)
HBV-DNA > 60 UI/mL 34 (39. 5%)
HBV-DNA unknown 02 (2. 32%)
HBV Genotype  
-genotype A 21
-genotype D 05
-genotype G 05
-genotype F 03
-CD4 cell count, median cells/μ1 545 (± 250)
-Baseline HIV RNA < 400 copies/mL 73 (85%)
ALT level, normal 54 (62. 7%)
- ALT level > 1. 5 × ULN† 32 (37. 2%)
-Anti-HCV positive 20 (23. 2%)
-Anti-HDV positive 01 (1. 1%)
  1. ULN†-Upper Limit of Normality; LAM = lamivudine; TDF = tenofovir